Journal article icon

Journal article

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study

Abstract:

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivotal studies with certain pre-existing cardiac conditions or baseline cardiac findings (PCCs), and those receiving beta blockers (BBs) and/or calcium channel blockers (CCBs), were eligible. Heart ra...

Expand abstract

Actions


Access Document


Publisher copy:
10.1007/s00415-013-7115-8

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Gottschalk, R More by this author
Expand authors...
Publisher:
Dr. Dietrich Steinkopff Verlag GmbH and Co. KG
Journal:
Journal of Neurology
Volume:
261
Issue:
2
Pages:
267-276
Publication date:
2014
DOI:
EISSN:
1432-1459
ISSN:
0340-5354
URN:
uuid:c1bb41bb-1eca-410e-bbbb-37b8f54c010d
Source identifiers:
464814
Local pid:
pubs:464814
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP